Evidence map›Paper›PMID 42165945›Full record

ArticleJournal of epidemiology and global health2026

Analysis of Infection Types, Pathogens, Antimicrobial Treatment, and Clinical Outcomes Data in Hospitalised Patients: Comprehensive Online Database for Antimicrobial Resistance (CODAR) Retrospective Pilot Study.

Andy Townsend, Naglaa Mohamed, Alona Kuraieva, Kristi Kuper, Alexandra Passarelli, Lili Jiang, Katherine Perez, Russell Outlaw, Vaughan Reed, Neera Hobson and 15 more

Abstract read
In one paragraph

Article in Journal of epidemiology and global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Andy TownsendPfizer Inc, Congleton, UK. andrew.townsend@pfizer.com.
Naglaa MohamedPfizer Inc, New York, NY, USA.
Alona KuraievaPfizer Inc, New York, NY, USA.
Kristi KuperPfizer Inc, Houston, TX, USA.
Alexandra PassarelliPfizer Inc, New York, NY, USA.
Lili JiangPfizer Inc, New York, NY, USA.
Katherine PerezPfizer Inc, New York, NY, USA.
Russell OutlawMicron Research Ltd, Ely, UK.
Vaughan ReedMicron Research Ltd, Ely, UK.
Neera HobsonMicron Research Ltd, Ely, UK.
Wendy WilkinsonMicron Research Ltd, Ely, UK.
Stuart BondPinderfields Hospital, Mid Yorkshire Teaching NHS Trust, Wakefield, UK.
Jade Lee-MilnerPinderfields Hospital, Mid Yorkshire Teaching NHS Trust, Wakefield, UK.
Kuldeep KumarFortis Healthcare Research Foundation (FHRF), Fortis Healthcare Ltd, Gurugram, India.
Anu GuptaFortis Escorts Heart Institute, New Delhi, India.
Ravneet KaurFortis, Noida, India.
Yashesh PaliwalFortis Hospital, Anandpur, Kolkata, India.
Rafael Franco-CendejasInstituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra (INRLGII), Mexico City, Mexico.
Alexandra Martin-OnraëtInstituto Nacional de Cancerología (INCAN), Mexico City, Mexico.
Juan Luis Mosqueda-GómezHospital Regional de Alta Especialidad del Bajío (HRAEB), Leon, Mexico.
Vicente EstradaHospital Clínico San Carlos, Instituto de investigación Sanitaria del Hospital Clínico San Carlos (IdiSSC), Ciberinfec, Madrid, Spain.
Ali SomilyCollege of Medicine, King Saud University and King Saud University Medical City (Riyadh), Riyadh, Saudi Arabia.
Anthony WilsonThe University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK.
Tim FeltonThe University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK.
Mahableshwar AlburSouthmead Hospital, North Bristol NHS Trust, Bristol, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEffective surveillance of prevalent infections, pathogen distribution, and treatment patterns help inform patient management and enhance outcomes. The Comprehensive Online Database for Antimicrobial Resistance (CODAR) pilot study aimed to provide insights into epidemiology, existing treatment strategies, and outcomes.

methodsThis surveillance study (February 2023-2024) across 21 hospitals in India, Mexico, Saudi Arabia, Spain, and the United Kingdom (UK) evaluated pathogen distribution, antimicrobial treatments, and survival rates in hospitalised patients using electronic health records and hospital reports.

resultsAmong 8060 eligible patient records, 7434 (92.2%) with complete data were included in this analysis. Urinary tract infections (UTI), predominantly occurring in female patients (59.0%), were the most prevalent across countries (29.0%). Comorbidities such as vascular and metabolic and nutritional disorders were most commonly observed across countries included in this study. Meropenem and amoxicillin-clavulanate were most commonly used antimicrobials in India and the UK, respectively, across most infection types. Patients with skin and skin structure infections had the highest survival rates (94.4%) and shortest hospital stay (mean [standard deviation], 20.6 [33.53] days), whereas those with bloodstream infections (BSI, 81.7%), mixed infections (82.1%), and lower respiratory tract infections (LRTI, 83.3%) had relatively lower survival rates. Low proportion of patients alive (≤55.0%) with both monotherapy and combination therapy were observed with Acinetobacter baumannii (LRTI), Klebsiella pneumoniae (LRTI and BSI), and Escherichia coli (UTI) in India and Staphylococcus aureus (SSSI) and Enterococcus faecium (UTI) in the UK.

conclusionLow survival rates associated with infections caused by specific pathogens highlight challenges in managing these infections, necessitating ongoing surveillance for effective infection control with suitable antimicrobial therapies to enhance patient care.

Indexed as

Anti-Bacterial AgentsAnti-Infective AgentsDrug Resistance, BacterialAdultAgedDatabases, FactualFemaleHospitalizationHumansIndiaMaleMiddle AgedPilot ProjectsRetrospective StudiesSaudi ArabiaUnited KingdomAnti-Bacterial AgentsAnti-Infective AgentsAntimicrobial treatmentElectronic health recordsHospitalised patientsInfectious diseasesLaboratory information management systemMicrobiological surveillanceMicrobiology laboratory data

Identifiers

PMID42165945
PMCPMC13391469

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.